

Final Beneficiaries active in any sector are eligible except the following activities:

- a) Activities targeting the production of weapons and ammunition, arms, military or police equipment or infrastructures, and equipment or infrastructure which result in limiting people's individual rights and freedom (i.e. prisons, detention centres of any form) or in violation of human rights;
- b) Activities targeting the production or facilitating the use of gambling and related equipment;
- c) Activities targeting tobacco manufacturing, processing, or specialist tobacco distribution, and activities facilitating the use of tobacco (e.g. "smoking halls");
- d) Activities involving live animals for experimental and scientific purposes insofar as compliance with the "Council of Europe's Convention for the Protection of Vertebrate Animals used for Experimental and other Scientific Purposes" cannot be guaranteed;
- e) Activities which give rise to environmental impacts that are not largely mitigated and/or compensated (see also section 3 about conformity with EU directives and national laws on environment);
- f) Activities considered ethically or morally controversial or which are forbidden by national law, e.g. research on human cloning;
- g) The purchase of goodwill; the purchase of intangible assets^[1] that could lead to or enforce a strong market position of the Final Beneficiary (i.e. a market share of more than 20% of the relevant market); the purchase of licenses or rights for mineral resource exploitation;
- h) Activities constituting pure real estate development activity;
- i) Activities constituting pure financial transactions (such as the purchase of shares, or any other financial product).
- j) Any other sectors identified as non-eligible sectors on the list of NACE codes available on the Millennium Leasing website https://www.millennium-leasing.pl/leasing_z_ebi

^[1] Examples of such intangible assets include production or distribution rights, such as for media and services, taxi licences, production licences in the pharmaceutical industry, etc.